Patent US534133A successfully refreshed from Google Patents.
Patent US4078073A successfully refreshed from Google Patents.
US4078073A
Expired / Lapsed
US
⏱️ 0.0 years remaining
N-tricyclic derivatives of azetidine
Assignee: Pfizer Italia SRL
•
Filing: 1976-11-02
•
Granted: 1978-03-07
•
Expires: 1996-11-02
Abstract
Abstract Novel N-tricyclic derivatives of azetidine of the formula: ##STR1## wherein A is a --CH 2 --O-- or an --O--CH 2 group, and the remaining substituents being defined in the specification are disclosed. An illustrative compound is 1-[11-(6,11-dihydro-dibenzo [b,e] oxepinyl)]-3-methylamino-azetidine. The compounds are useful for their anti-depressant, anti-convulsant and anxiolytic activities.
Inventors
- 👤 Piero Melloni
- 👤 Arturo Della Torre
- 👤 Francesco Lauria
- 👤 Norina Passerini
- 👤 Alessandro Rossi
- 👤 Raffaele Tommasini
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 13:11
CPC Classifications
C; C07; C07D; C07D205/00; C07D205/02; C07D205/04
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
81 words
A compound of formula: ##STR15## wherein: n 1 is zero or 1 R 5 and R 6 each independently represent hydrogen or C 1 -C 6 alkyl; and one of the Y groups is hydrogen and the other is hydrogen, halogen, C 1 -C 6 alkoxy, trifluoromethyl or methylsulphonyl, provided that, when n 1 is zero, the ##STR16## radical is exclusively bound to the carbon atom in the 3-position of the azetidine radical, and the salts thereof with pharmaceutically acceptable acids.
Claim 2
Dependent Claim
81 words
A compound of formula: ##STR15## wherein: n 1 is zero or 1 R 5 and R 6 each independently represent hydrogen or C 1 -C 6 alkyl; and one of the Y groups is hydrogen and the other is hydrogen, halogen, C 1 -C 6 alkoxy, trifluoromethyl or methylsulphonyl, provided that, when n 1 is zero, the ##STR16## radical is exclusively bound to the carbon atom in the 3-position of the azetidine radical, and the salts thereof with pharmaceutically acceptable acids.
Claim 3
Dependent Claim
6 words
1-[11-(6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylamino-azetidine, as claimed in claim 1.
Claim 4
Dependent Claim
6 words
1-[11-(2-chloro-6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylamino-azetidine, as claimed in claim 1.
Claim 5
Dependent Claim
6 words
1-[11-(9-chloro-6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylamino-azetidine, as claimed in claim 1.
Claim 6
Dependent Claim
6 words
1-[11-(2-trifluoromethyl-6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylamino-azetidine, as claimed in claim 1.
Claim 7
Dependent Claim
6 words
1-[11-(9-trifluoromethyl-6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylamino-azetidine, as claimed in claim 1.
Claim 8
Dependent Claim
6 words
1-[11-(2-methoxy-6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylamino-azetidine, as claimed in claim 1.
Claim 9
Dependent Claim
6 words
1-[11-(9-methoxy-6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylamino-azetidine, as claimed in claim 1.
Claim 10
Dependent Claim
6 words
1-[11-(2-methylsulphonyl-6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylamino-azetidine, as claimed in claim 1.
Claim 11
Dependent Claim
6 words
1-[11-(9-methylsulphonyl-6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylamino-azetidine, as claimed in claim 1.
Claim 12
Dependent Claim
6 words
1-[11-(6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylaminomethyl-azetidine, as claimed in claim 1.
Claim 13
Dependent Claim
6 words
1-[11-(6,11-dihydro-dibenzo[b,e]oxepinyl)]-2-methylamino-methyl-azetidine, as claimed in claim 1.
Claim 14
Independent Claim
29 words
A method of treating central nervous system depression consisting essentially of administering to a person suffering therefrom an effective amount of compound 1-[11-(6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylamino-azetidine, and the pharmaceutically acceptable salts thereof.
Claim 15
Independent Claim
29 words
A method of treating central nervous system depression consisting essentially of administering to a person suffering therefrom an effective amount of compound 1-[11-(6,11-dihydro-dibenzo[b,e]oxepinyl)]-3-methylamino-azetidine, and the pharmaceutically acceptable salts thereof.
Claim 16
Dependent Claim
20 words
The method of claim 13 wherein from 20 to 50 mg. of the compound is administered 2-4 times a day.
Claim 17
Dependent Claim
26 words
An anti-convulsant pharmaceutical composition containing, as the active ingredient thereof, an effective amount of a compound of claim 1, together with a suitable carrier or diluent.
Claim 18
Dependent Claim
22 words
A method of treating convulsions consisting of administering to a person suffering therefrom an effective amount of a compound of claim 1.
References Cited (Backward Citations)
US3509176A
Cited
US3991103A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-03-06 | 1981-09-05 | 1982-03-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-03-06 | 1985-09-05 | 1986-03-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-03-06 | 1989-09-05 | 1990-03-07 | $7700.00 | Window Closed / Lapsed |